Digital Therapeutics Companies Face a Tripled Administrative Load
Building a digital therapeutic is hard. Getting it reimbursed is harder. Doing both simultaneously — while running clinical studies, managing regulatory submissions, and piloting with payers — creates an administrative load that most DTx teams are not staffed to handle.
The Digital Therapeutics Alliance reported in 2024 that more than 70% of DTx companies have fewer than 50 employees. Yet these companies are simultaneously navigating FDA Software as a Medical Device (SaMD) pathways, running randomized controlled trials, and pitching coverage to Pharmacy Benefit Managers (PBMs) and managed care organizations. The administrative infrastructure required to support all three tracks is enormous — and it's rarely what the founding team was hired to build.
Virtual assistants (VAs) with healthcare operations experience are increasingly deployed by DTx companies to manage the coordination work across all three tracks: payer pilots, regulatory submissions, and clinical study administration.
Payer Pilot Admin: Keeping Reimbursement Pathways Moving
Payer pilots are how most DTx products move from "interesting technology" to covered benefit. A typical pilot involves contracting with a health plan or employer, enrolling a member cohort, collecting outcomes data, and presenting results to the plan's formulary committee or value-based committee. Each step generates coordination work.
A VA manages payer pilot administration: preparing meeting materials for pilot kickoff and steering committee calls, tracking enrollment against targets, coordinating data reporting cadences with the plan's analytics team, maintaining the contract and amendment log, and following up on outstanding deliverables from either side. According to a 2023 analysis by Rock Health, DTx companies that ran structured pilot programs with dedicated coordination support reached coverage decisions 40% faster than those managing pilots informally.
When the payer asks for data, the VA ensures it's ready. When a milestone is at risk, the VA surfaces it before it becomes a problem.
Regulatory Submission Tracking: Keeping FDA Processes on Schedule
For DTx products pursuing FDA De Novo classification, 510(k) clearance, or Breakthrough Device designation, submission management is a multi-month, multi-document process with hard deadlines. The FDA's Q-Submission program requires coordinated meeting requests, pre-submission packages, and response tracking — all of which generate administrative work separate from the scientific and regulatory writing itself.
A VA handling regulatory submission tracking maintains a master timeline with all regulatory milestones, submission deadlines, and FDA correspondence dates. They coordinate document collection from clinical, quality, and engineering teams, track the status of each submission component, and schedule internal review meetings to ensure submissions don't miss deadlines due to coordination failures.
According to the FDA's 2023 CDRH performance data, 28% of De Novo submissions that received refuse-to-accept notices cited incomplete administrative documentation — issues that diligent coordination could prevent. A VA can't write the regulatory strategy, but they can ensure the filing is complete, organized, and submitted on time.
Clinical Study Coordination: Supporting the Evidence Generation Engine
DTx companies that want payer coverage need clinical evidence. Running that evidence requires coordinating with clinical sites, IRBs, CROs, and patient recruitment vendors — all of which generate ongoing administrative demands.
A VA supporting clinical study coordination handles: IRB submission tracking and renewal reminders, site initiation visit scheduling, investigator meeting logistics, data entry monitoring coordination, adverse event documentation routing, and trial master file organization. According to the Association of Clinical Research Organizations (ACRO), administrative coordination failures — missed renewals, incomplete site documentation, late data queries — account for 18% of clinical study delays.
A VA who owns the coordination calendar for an ongoing study prevents those delays by building the follow-up infrastructure that busy CROs and regulatory affairs managers rarely have bandwidth to maintain.
The Financial Case for DTx Companies
DTx companies at the Series A and B stage are managing cash carefully. A full-time clinical operations coordinator commands $70,000–$90,000 per year. A VA covering a meaningful portion of that scope — payer pilot tracking, regulatory submission coordination, clinical study admin — runs at a fraction of that cost, often $15–$25 per hour, with hours scaling to workload.
For companies operating on 18-month runways, that cost structure makes a difference.
Protect the Science. Delegate the Admin.
The value of a digital therapeutic is in its clinical evidence and its reimbursement pathway. Everything else is coordination. A virtual assistant from Stealth Agents gives DTx teams the administrative infrastructure to run payer pilots, hit regulatory deadlines, and keep clinical studies on track — without diverting scientific talent to logistics.
Sources
- Digital Therapeutics Alliance, DTx Industry Report, 2024
- Rock Health, Digital Health Coverage and Reimbursement Analysis, 2023
- FDA Center for Devices and Radiological Health (CDRH), Performance Report, 2023
- Association of Clinical Research Organizations (ACRO), Clinical Study Operations Benchmarks, 2023
- U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics, 2024